Whitney Ijem
Stock Analyst at Canaccord Genuity
(2.13)
# 2,817
Out of 4,761 analysts
88
Total ratings
34.25%
Success rate
-0.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $39 | $19.22 | +102.91% | 1 | Feb 20, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 → $136 | $42.59 | +219.32% | 8 | Feb 18, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $384 → $385 | $250.59 | +53.64% | 7 | Feb 18, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Hold | $408 → $424 | $484.24 | -12.44% | 8 | Feb 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $80 | $56.07 | +42.68% | 5 | Nov 19, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 | $10.47 | +272.49% | 5 | Nov 19, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 | $12.17 | +639.52% | 5 | Nov 19, 2024 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $6 → $8 | $1.61 | +396.89% | 8 | Nov 15, 2024 | |
| PASG Passage Bio | Maintains: Buy | $13 | $0.52 | +2,377.13% | 6 | Nov 14, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $148 → $150 | $106.28 | +41.14% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $32 | $7.28 | +339.56% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $68.25 | +23.08% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 | $1.11 | +1,341.44% | 5 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $28 | $1.31 | +2,037.40% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $86 | $17.77 | +383.96% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.61 | +1,374.93% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $109.95 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $16 | $0.60 | +2,573.80% | 4 | Jul 23, 2019 |
Palvella Therapeutics
Feb 20, 2025
Initiates: Buy
Price Target: $39
Current: $19.22
Upside: +102.91%
Ultragenyx Pharmaceutical
Feb 18, 2025
Maintains: Buy
Price Target: $121 → $136
Current: $42.59
Upside: +219.32%
Alnylam Pharmaceuticals
Feb 18, 2025
Maintains: Buy
Price Target: $384 → $385
Current: $250.59
Upside: +53.64%
Vertex Pharmaceuticals
Feb 12, 2025
Upgrades: Hold
Price Target: $408 → $424
Current: $484.24
Upside: -12.44%
Rhythm Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $80
Current: $56.07
Upside: +42.68%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $39
Current: $10.47
Upside: +272.49%
Intellia Therapeutics
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $12.17
Upside: +639.52%
Taysha Gene Therapies
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.61
Upside: +396.89%
Passage Bio
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.52
Upside: +2,377.13%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $106.28
Upside: +41.14%
Nov 6, 2024
Maintains: Buy
Price Target: $29 → $32
Current: $7.28
Upside: +339.56%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $68.25
Upside: +23.08%
Oct 18, 2024
Maintains: Buy
Price Target: $16
Current: $1.11
Upside: +1,341.44%
Jun 25, 2024
Maintains: Buy
Price Target: $11 → $28
Current: $1.31
Upside: +2,037.40%
May 10, 2024
Maintains: Buy
Price Target: $87 → $86
Current: $17.77
Upside: +383.96%
Nov 8, 2022
Initiates: Buy
Price Target: $9
Current: $0.61
Upside: +1,374.93%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $109.95
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $8 → $16
Current: $0.60
Upside: +2,573.80%